The drug industry has been ordered to rectify the mystery of related transactions

Every reporter Yeu Qi from Chengdu Cologne Pharmaceutical Industry (002422) less than half a year to receive two orders to rectify the "ticket", and two violations behind a company figure. Within six months of two "tickets" Yesterday (April 16), the Cologne pharmaceutical Industry Bulletin said that the company 14th received the decision of the Sichuan Securities Regulatory Bureau to order corrective measures, the company chairman and the actual control of Chengdu Liu Genue Trading Co., Ltd. (hereinafter referred to as Chengdu Gioui) major business activities can be implemented control, Chengdu Long Easy to have a relationship with the company. However, the company did not disclose the relevant relationship and related transactions with Chengdu Gioui and its subsidiaries. The company announced that the above acts violate the provisions of article II and 48th of the Regulations on information disclosure of listed companies. In accordance with the provisions of regulation 59th of information disclosure management of listed companies, the company is ordered to take measures to correct the above problems, to hold the relevant personnel responsible, to ensure that the company standardize operation, information disclosure is true, accurate, complete, timely and fair. In accordance with the relevant regulations, the Cologne pharmaceutical industry shall, within 2 working days after receiving the above order corrective measures, disclose and notify the controlling shareholder and the actual controller, and submit a written rectification report to the Sichuan authority within 30 working days. The rectification report shall include corrective action, expected completion time, rectification of the responsible person, rectification and implementation. In fact, last year, the pharmaceutical industry has issued a notice that the Sichuan Securities and Regulatory Bureau in the company's on-site inspection, made the "Sichuan Cologne Pharmaceutical Co., Ltd. to take orders to rectify the decision," pointed out that there is no disclosure of the company's external security subsidiaries, some intangible assets disclosed incomplete, The disclosure of the reasons for the delay of the individual investment projects; In addition, in the use of fund-raising, there are some projects to raise funds to use irregular and individual projects raise funds replacement is not standardized. and Chengdu Gioui had 360 million transactions in Cologne pharmaceutical industry December 26, 2013 released the rectification report shows that the Cologne pharmaceutical holding subsidiary Yili Twinings Biotechnology Co., Ltd. (hereinafter referred to as Yili Twinings) and Chengdu Gioui transactions, involving 360 million of the use of funds not standardized. 2011, the Ili Twinings and Chengdu, the long easy procurement contract between the implementation process, the company accumulated over the fund to pay the contract price of 360 million, due to the transaction amount adjustment, Chengdu long Easy return to the company to raise funds 328 million yuan, this part of the refund did not return the company to raise funds special account. It is noteworthy that the Sichuan Securities and Regulatory Bureau specifically on the Liu Innovation and Chengdu Gioui Actual control relations and related Transactions issues issued rectification notice. And the reporter inquires the industrial and commercial system discovery, Chengdu long Easy by 2 natural person shareholder in November 2010 investment establishment. Public information shows that Chengdu long easy to operate second-hand 135MW intermediate reheat condensing steam turbine. From the view of the shareholding structure, Liu Genue to Chengdu, "major business activities can be implemented control" seems to come from the relationship between natural persons, and this is the most difficult to be perceived by the outside association. The above 360 million-related transaction was considered by the Sichuan Securities Regulatory Bureau as violating the rules for the use of fund-raising funds. But knotWith yesterday's announcement, if Liu Genue's time for Chengdu to "control" has been generated since 2011, then the deal is likely to be included in the relevant transactions, and the Cologne pharmaceutical industry has not been disclosed. In addition, the Xinjiang antibiotic project involving the Ili Twinings and Chengdu Long Yi Exchange is controversial due to contract litigation. Dai, a person who has a lawsuit relationship with the Cologne pharmaceutical industry, told the Daily economic news that it had reported several irregularities to the Sichuan Securities Regulatory Bureau in February this year. Dai that the disclosure of the company's hidden links is only part of the issue, he will continue to report to the authorities. In this respect, the drug industry director of the Department of the staff of the "Daily economic news" Reporter said that the company is currently self-examination, inconvenient to express their views. The son of Liu Genue and Liu Sichao, director of the pharmaceutical industry in Cologne, also said that it was inconvenient to respond.